Pargluva Poses 'Excess' Safety Risks, JAMA Study Says

Drug Industry Daily
KEYWORDS FDA / Trial
A A

If approved by the FDA, Merck and Bristol-Myers Squibb’s (BMS) highly anticipated diabetes treatment Pargluva would “constitute an unacceptable patient hazard,” according to an independent clinical analysis that shows the drug poses significant safety risks.

To View This Article:

Login

Subscribe To Drug Industry Daily